1092565-35-9

Basic information

• Product Name: 2,4-difluoro-N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide
• Synonyms: 2,4-difluoro-N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide
• CAS NO: 1092565-35-9
• Molecular Weight: 396.223
• Mol File: 1092565-35-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2,4-difluoro-N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-difluoro-N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide(1092565-35-9)
• EPA Substance Registry System: 2,4-difluoro-N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide(1092565-35-9)

Safety Data

• Hazardous Substances Data: 1092565-35-9(Hazardous Substances Data)

Upstream product

• 13535-01-8 3-amino-5-bromopyridine 
• 13918-92-8 2,4-difluorobenzene-1-sulfonyl chloride 
• 1083326-23-1 N-(5-bromo-3-pyridinyl)-2,4-difluorobenzenesulfonamide 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1605327-61-4 (S)-N-(5-(4-amino-6-((1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl)amino)pyrimidin-5-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1400667-74-4 N-(5-(4-(tetrahydro-2H-pyran-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 

Relevant articles and documents

Identification of novel thiazolo[5,4-b]pyridine derivatives as potent phosphoinositide 3-kinase inhibitors

A series of novel 2-pyridyl, 4-morpholinyl substituted thiazolo[5,4-b]pyridine analogues have been designed and synthesized in this paper. These thiazolo[5,4-b]pyridines were efficiently prepared in seven steps from commercially available substances in mo

NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PB kinases using naphthyridine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of naphthyridine derivatives.